TRANSCATHETER HEART VALVE MARKET ANALYSIS

Transcatheter Heart Valve Market, By Product Type (TAVR, TMVR), By Delivery Systems (Transfemoral Approach, Transapical Approach, Transaortic Approach), By End User (Hospitals, Ambulatory Surgical Centers, Cardiac Catheterization Laboratory), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Global Transcatheter Heart Valve Market: Key Developments

Key players in the market are focused on product approvals, which is expected to drive the global transcatheter heart valve market growth over the forecast period. For instance, in September 2022, Edwards Lifesciences, a medical technology company, received U.S. FDA approval for the latest generation of its Sapien 3 transcatheter aortic valve, which is outfitted with materials that the company claims will form the foundation of future heart valve implants.
In August 2021, Medtronic, a medical device company, announced the U.S. Food and Drug Administration (FDA) approval of its newest-generation, self-expanding transcatheter aortic valve replacement (TAVR) system, the Evolut FX TAVR system.
In May 2021, Abbott, a multinational medical devices and health care company, announced that it had received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, making the minimally invasive device available for people in Europe with severe aortic stenosis who are at high or extreme surgical risk.